about
Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucomaPrevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study.Utilization of various glaucoma surgeries and procedures in Medicare beneficiaries from 1995 to 2004.Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006.Use of retinal procedures in medicare beneficiaries from 1997 to 2007.Copy number variations on chromosome 12q14 in patients with normal tension glaucomaUpdate on prostaglandin analogs.Risk factors for age related cataract in a rural population of southern India: the Aravind Comprehensive Eye StudyThe ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?Confirmation of TBK1 duplication in normal tension glaucomaDoes adjunctive glaucoma therapy affect adherence to the initial primary therapy?Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspective.Identification of proteins that interact with TANK binding kinase 1 and testing for mutations associated with glaucoma.Influence of parental health literacy and dosing responsibility on pediatric glaucoma medication adherencePatient-reported barriers to glaucoma medication access, use, and adherence in southern India.Population-based prevalence of uveitis in Southern India.First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008.An objective evaluation of eyedrop instillation in patients with glaucoma.A video study of drop instillation in both glaucoma and retina patients with visual impairment.Compliance and adherence in glaucoma management.Predictors of and barriers associated with poor follow-up in patients with glaucoma in South India.Pseudoexfoliation in a rural population of southern India: the Aravind Comprehensive Eye Survey.Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey.Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.Female reproductive factors and eye disease in a rural South Indian population: the Aravind Comprehensive Eye Survey.Medical treatment patterns of ASCRS members for primary open-angle glaucoma--1998 survey.Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial.Glaucoma surgery treatment patterns of ASCRS members--2000 survey.Self-reported prevalence and factors associated with nonadherence with glaucoma medications in veteran outpatients.The Madurai Intraocular Lens Study I-III.A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.Evaluation of Medicare costs of endophthalmitis among patients after cataract surgery.Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.Patient preferences for eye drop characteristics: a willingness-to-pay analysis.Glaucoma clinical trials.Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression.Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss.Patient-reported behavior and problems in using glaucoma medications.Algorithm for interpreting the results of frequency doubling perimetry.
P50
Q28308284-E601F5B2-D55F-42C3-944F-CE9C174F51EDQ33201414-F51AEDEF-300A-4E1E-85BD-038A5B545E55Q33283095-F05345AC-2D95-456A-85E3-63F0EE278C74Q33481589-48410205-8FCD-48F8-A2DA-03CE61A8DA01Q33715288-D748E443-6026-4AF8-96C9-5A96F86C6588Q34994800-CED8308F-BF2D-46DA-8778-419460A3633FQ35108060-ADEB2A8C-02FC-4ABE-B77F-33DB3A84BB26Q35592350-21738089-F740-4B86-8B8F-1856D8DC148BQ35684913-354A0529-B48D-4797-8C06-CC42E90D9D62Q35812584-9389AEE6-EB08-450A-B310-7BC270C7E60DQ36118810-FD398B70-0182-41B1-9E7F-75B12EBBABFFQ36965079-D1424996-5CD7-4861-8D35-F0A674B90FF3Q36979277-6AC5C533-593B-4E7F-A850-625AB048E2DFQ37023981-31E596B4-659A-4AF7-9819-7BE394466931Q37141614-C2616B89-1401-45B0-AEE1-E9BB8F3E051FQ37778677-8E66A3B6-082A-4C32-90AF-0134F0F3113BQ37806200-893FA40D-6580-4300-9FDF-5F0ED85D23A9Q38380972-BFB29370-68F7-41B1-B77D-89823AE77C4EQ39720474-1A8F7836-ABAB-4762-A93B-0E2C9C296339Q41763942-AABB53DD-B2A2-4803-B93B-F72B5231F1FCQ42600071-3005F1D4-9A60-44B9-8C1C-87662CA9C1FEQ42600841-FBD41A14-B52A-4D12-AFE7-9AF928FED8F3Q42605877-0A261290-6C09-4D9D-B243-41A19B185000Q42628471-B534B6FB-D571-47BD-889F-0077909363B1Q42641166-83713BEA-4605-4440-922E-151512F9AED3Q42689853-935BE726-A7B4-474E-AC14-3220922A1BAFQ43291442-7EF8BFD4-C078-4674-B7C1-FF04127AD699Q43799919-254795C4-A443-4B6D-ADC1-1FBF2DBAFEFAQ44055389-2F3CD170-3741-47E8-BA20-D2749A35491BQ44377675-4A8978DD-E821-43DE-982E-D512A57FBCEEQ44466517-C4DEFE34-CD1A-466E-B0CD-8AAEDED0016AQ44927398-92F7490D-2478-49A6-A219-390805927FEFQ45967286-F2A1E1B2-01BF-4455-BC0A-A128598C69A8Q46369789-03D20AC1-51BA-4C17-8ADE-B477D89B1453Q47974014-C37550A6-8858-48E2-BDE3-5B3B5BEF002AQ48230127-D9D50B88-7249-4DC6-AB8B-FAFDE989926AQ50788872-B7626003-1842-4C40-812B-400D4DF2DF86Q51557402-44E46874-9082-4733-8FC6-2F6AE6ECE8E8Q51984996-4D091842-807B-4028-991E-B3A2262E9255Q52081402-71457490-E30A-4725-9400-6430C64EE9B4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan L Robin
@nl
Alan L Robin
@sl
Alan L. Robin
@en
Alan L. Robin
@es
type
label
Alan L Robin
@nl
Alan L Robin
@sl
Alan L. Robin
@en
Alan L. Robin
@es
prefLabel
Alan L Robin
@nl
Alan L Robin
@sl
Alan L. Robin
@en
Alan L. Robin
@es
P106
P1153
35373759700
P21
P31
P496
0000-0003-1959-8770